Xiao Gan Shi

Researchers are evaluating a new treatment regimen called MA+AZA, which combines mitoxantrone hydrochloride liposomes with cytarabine and azacitidine, for patients newly diagnosed with acute myeloid leukemia (AML). This Phase 3, prospective, multicenter, randomized controlled study compares the MA+AZA regimen to the traditional DA+AZA chemotherapy regimen to determine which provides better induction treatment for primary AML. The goal is to observe the effectiveness and safety of the new combination and gather high-quality clinical evidence to improve treatment outcomes and prognosis for AML patients. Participants are randomly assigned to receive either the MA+AZA regimen or the DA+AZA regimen. The MA+AZA group receives mitoxantrone hydrochloride liposome 24 mg/m2 intravenously on day 1 every 4 weeks, cytarabine 100 mg/m2 intravenously every 12 hours from days 1 to 7, and azacitidine 100 mg subcutaneously once daily from days 1 to 7. The DA+AZA group receives daunorubicin 60 mg/m2 intravenously once daily from days 1 to 3, cytarabine 100 mg/m2 intravenously every 12 hours from days 1 to 7, and azacitidine 100 mg subcutaneously once daily from days 1 to 7. During the study, participants are monitored to evaluate the complete remission rate 2 to 3 weeks after the first 28-day treatment cycle. Researchers assess treatment efficacy and safety through clinical evaluations and laboratory tests. The study includes patients aged 18 to 75 years with confirmed AML and adequate liver, kidney, and heart function, with performance status scores between 0 and 2. Informed consent is obtained from all participants or their families before enrollment.

Researchers are evaluating an artificial intelligence-based multimodal cognitive screening system designed to identify mild cognitive impairment related to type 2 diabetes mellitus (T2DM) early on. This observational study focuses on patients aged 40 to 75 years who have memory complaints and aims to determine how well the AI system can detect cognitive changes over a 3 to 5 year follow-up period. The study also examines the relationship between diabetic metabolic indicators, such as glycemic variability and HbA1c levels, and changes in cognitive function to assess the value of early detection and intervention in these patients. Participants will undergo follow-up observation for 3 to 5 years without additional interventions. Cognitive status data will be collected at the start of the study and at the end of the follow-up period to monitor changes over time. No medications or treatments will be administered as part of the study; the focus is solely on observing cognitive function and diabetes-related metabolic factors. During the study, participants' cognitive abilities will be regularly assessed using the AI screening system. Researchers will collect data on cognitive deterioration rates and the accuracy of early identification by the AI tool. The study includes monitoring participants' ability to perform daily activities and tracking memory-specific deficits, with follow-up lasting up to five years to capture long-term cognitive outcomes and safety.

Nausea and vomiting during pregnancy (NVP) is a common and challenging problem in the first trimester that significantly affects the quality of life of pregnant women. Current treatments are limited due to concerns about drug safety for the embryo and discomfort associated with traditional acupuncture methods. This study evaluates the clinical efficacy and safety of thumbtack needle (TN), a type of shallow puncture intradermal needle, as a treatment for moderate to severe NVP. The trial is a multi-center, large-sample, randomized, controlled, and blinded clinical study designed to provide high-quality evidence on TN's effects on nausea, vomiting, quality of life, anxiety, depression, and various pregnancy and neonatal outcomes. Participants receive either real thumbtack needle treatment or a sham thumbtack needle that looks similar but lacks the needle body and stimulation. The TN is applied to specific acupoints and retained for 3 days before removal and reapplication by a doctor, with a total of five treatments over 15 days. The sham treatment group follows the same schedule and procedures without the needle effect. This approach aims to compare the effects of continuous and stable stimulation by TN against a placebo-like control. During the study, participants are assessed for changes in nausea and vomiting using the Pregnancy Unique Quantification of Emesis (PUQE) scale from baseline to day 15. Researchers also monitor weight changes, anxiety and depression levels, blood electrolyte levels, liver and kidney function, thyroid function, use of intravenous fluids and additional drugs, hospital admissions, pregnancy complications, and both pregnancy and neonatal outcomes. Safety and adherence are closely observed throughout the 15-day treatment period.